



Certificate

No. Q5 117896 0001 Rev. 01

Holder of Certificate: **ADmit Therapeutics, S.L.**
C/ Joan XXIII 10
08950 Esplugues de Llobregat, Barcelona
SPAIN

Certification Mark:



Scope of Certificate: **Design and Development, Production of in-vitro diagnostic reagents for genetic testing for epigenetic changes.**
Design and Development, Production and Service of in-vitro diagnostic software for nucleic acid testing (NGS data analysis for Human mitochondrial DNA methylation patterns).

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the Testing, Certification, Validation and Verification Regulations TÜV SÜD Group have to be complied with. For details and certificate validity see: [www.tuvsud.com/ps-cert?q=cert:Q5 117896 0001 Rev. 01](http://www.tuvsud.com/ps-cert?q=cert:Q5_117896_0001_Rev_01)

Report No.: ITA200220000369

Valid from: 2024-05-07

Valid until: 2026-06-13

Date, 2024-05-07

Christoph Dicks
Head of Certification/Notified Body

Certificate

No. Q5 117896 0001 Rev. 01

Applied Standard(s): ISO 13485:2016
(EN ISO 13485:2016/AC:2018, EN ISO 13485:2016/A11:2021)
Medical devices - Quality management systems -
Requirements for regulatory purposes

Facility(ies): **ADmit Therapeutics, S.L.**
C/ Joan XXIII 10, 08950 Esplugues de Llobregat, Barcelona,
SPAIN

Design and Development, Production of in-vitro diagnostic reagents for genetic testing for epigenetic changes.
Design and Development, Production and Service of in-vitro diagnostic software for nucleic acid testing (NGS data analysis for Human mitochondrial DNA methylation patterns).

/



COLLEGE of AMERICAN
PATHOLOGISTS

CERTIFICATE OF ACCREDITATION

**ADmit Therapeutics
Laboratory
Esplugues LLobregat, Spain
Marta Blanch Lozano, PhD**

CAP#: 9373261

The organization named above meets all applicable standards for accreditation and is hereby accredited by the College of American Pathologists' Laboratory Accreditation Program. Reinspection should occur prior to **September 20, 2026** to maintain accreditation.

Accreditation does not automatically survive a change in director, ownership, or location and assumes that all interim requirements are met.

Kathleen G. Beavis, MD
Chair, Accreditation Committee

Donald S. Karcher, MD, FCAP
President, College of American Pathologists

